PMID- 26900843
OWN - NLM
STAT- MEDLINE
DCOM- 20160726
LR  - 20190222
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 2
DP  - 2016
TI  - Cell Treatment for Stroke in Type Two Diabetic Rats Improves Vascular 
      Permeability Measured by MRI.
PG  - e0149147
LID - 10.1371/journal.pone.0149147 [doi]
LID - e0149147
AB  - Treatment of stroke with bone marrow stromal cells (BMSC) significantly enhances 
      brain remodeling and improves neurological function in non-diabetic stroke rats. 
      Diabetes is a major risk factor for stroke and induces neurovascular changes 
      which may impact stroke therapy. Thus, it is necessary to test our hypothesis 
      that the treatment of stroke with BMSC has therapeutic efficacy in the most 
      common form of diabetes, type 2 diabetes mellitus (T2DM). T2DM was induced in 
      adult male Wistar rats by administration of a high fat diet in combination with a 
      single intraperitoneal injection (35mg/kg) of streptozotocin. These rats were 
      then subjected to 2h of middle cerebral artery occlusion (MCAo). T2DM rats 
      received BMSC (5x106, n = 8) or an equal volume of phosphate-buffered saline 
      (PBS) (n = 8) via tail-vein injection at 3 days after MCAo. MRI was performed one 
      day and then weekly for 5 weeks post MCAo for all rats. Compared with vehicle 
      treated control T2DM rats, BMSC treatment of stroke in T2DM rats significantly 
      (p<0.05) decreased blood-brain barrier disruption starting at 1 week post stroke 
      measured using contrast enhanced T1-weighted imaging with gadopentetate, and 
      reduced cerebral hemorrhagic spots starting at 3 weeks post stroke measured using 
      susceptibility weighted imaging, although BMSC treatment did not reduce the 
      ischemic lesion volumes as demarcated by T2 maps. These MRI measurements were 
      consistent with histological data. Thus, BMSC treatment of stroke in T2DM rats 
      initiated at 3 days after stroke significantly reduced ischemic vascular damage, 
      although BMSC treatment did not change infarction volume in T2DM rats, measured 
      by MRI.
FAU - Ding, Guangliang
AU  - Ding G
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Chen, Jieli
AU  - Chen J
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Chopp, Michael
AU  - Chopp M
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
AD  - Department of Physics, Oakland University, Rochester, Michigan, 48309, United 
      States of America.
FAU - Li, Lian
AU  - Li L
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Yan, Tao
AU  - Yan T
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
AD  - Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 
      300052, China.
FAU - Li, Qingjiang
AU  - Li Q
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Cui, Chengcheng
AU  - Cui C
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Davarani, Siamak P N
AU  - Davarani SP
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
FAU - Jiang, Quan
AU  - Jiang Q
AD  - Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, 
      Michigan, 48202, United States of America.
LA  - eng
GR  - NS064134/NS/NINDS NIH HHS/United States
GR  - R41 NS080329/NS/NINDS NIH HHS/United States
GR  - AG037506/AG/NIA NIH HHS/United States
GR  - R01 AG037506/AG/NIA NIH HHS/United States
GR  - R01 NS064134/NS/NINDS NIH HHS/United States
GR  - R41 S080329/PHS HHS/United States
GR  - R01 NS083078/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160222
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Blood-Brain Barrier/metabolism/pathology
MH  - *Capillary Permeability
MH  - *Cell- and Tissue-Based Therapy/methods
MH  - Cerebral Hemorrhage/diagnosis/etiology
MH  - Diabetes Mellitus, Experimental
MH  - Diabetes Mellitus, Type 2/complications/*metabolism
MH  - Disease Models, Animal
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells
MH  - Rats
MH  - Stroke/complications/*diagnosis/etiology/*metabolism/therapy
PMC - PMC4762715
COIS- Competing Interests: No conflicts are declared for all authors. The content is 
      solely the responsibility of the authors and does not necessary represent the 
      official view of the National Institute of Health.
EDAT- 2016/02/24 06:00
MHDA- 2016/07/28 06:00
PMCR- 2016/02/22
CRDT- 2016/02/23 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/01/27 00:00 [accepted]
PHST- 2016/02/23 06:00 [entrez]
PHST- 2016/02/24 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
PHST- 2016/02/22 00:00 [pmc-release]
AID - PONE-D-15-49184 [pii]
AID - 10.1371/journal.pone.0149147 [doi]
PST - epublish
SO  - PLoS One. 2016 Feb 22;11(2):e0149147. doi: 10.1371/journal.pone.0149147. 
      eCollection 2016.